Folate
What it is
Folate is a water-soluble B vitamin (B9) essential for DNA synthesis, cell division, and amino acid metabolism. It is found naturally in leafy green vegetables, legumes, liver, and some fortified foods. The term folate refers to the naturally occurring forms of the vitamin found in food. Folic acid refers to the synthetic oxidised form used in supplements and food fortification, which has higher bioavailability than food folate under fasting conditions but must be converted to active forms in the body.
Folate plays a central role in one-carbon metabolism, a network of biochemical reactions that include DNA methylation, nucleotide synthesis, and the conversion of homocysteine to methionine. This metabolic centrality explains folate's importance in rapidly dividing cells, its clinical relevance in pregnancy, its relationship to homocysteine levels, and why its metabolism is particularly sensitive to genetic variation.
The conversion of folic acid to the active form 5-methyltetrahydrofolate (5-MTHF) requires a multi-step enzymatic process, including a reaction catalysed by the enzyme methylenetetrahydrofolate reductase (MTHFR). This conversion step is where genetic variation has the most clearly established clinical relevance.
Supplemental forms include folic acid, the most widely used and studied form; methylfolate (5-MTHF, available in several branded preparations), the active end form that does not require enzymatic conversion; and folinic acid (5-formyltetrahydrofolate), another active form used in some clinical contexts.
What the evidence shows
Neural tube defect prevention in the periconceptional period is where the evidence is strongest and the clinical stakes are highest. The MRC Vitamin Study (1991) demonstrated a 72 per cent reduction in neural tube defect recurrence with periconceptional folic acid supplementation in women with a previous affected pregnancy. Czeizel and Dudas (1992) demonstrated a significant reduction in first occurrence in a large Hungarian RCT. These findings have been replicated in observational studies across multiple countries and have formed the basis for public health supplementation recommendations worldwide. Current UK guidance recommends 400 mcg folic acid daily for all women planning pregnancy, starting before conception and continuing through the first 12 weeks. Women at higher risk, including those with a previous neural tube defect-affected pregnancy, are recommended 5 mg daily.
An important qualification: this evidence applies specifically to the periconceptional period. Supplementation initiated after neural tube closure, which occurs by approximately six weeks of gestation, does not provide the same preventive benefit for that pregnancy.
Deficiency correction is well-evidenced across multiple trials. Oral folate supplementation at adequate doses reliably restores serum and red cell folate in deficient individuals.
Homocysteine reduction in folate-deficient individuals is a consistent and well-characterised biochemical effect. As with B12, however, homocysteine reduction is best understood as an exploratory biomarker effect rather than a validated clinical surrogate. Large well-powered trials including the HOPE-2 trial and meta-analyses of B-vitamin supplementation trials have consistently found that homocysteine lowering does not translate to reductions in major cardiovascular events. The biochemical effect is reliable; its clinical translation is not demonstrated.
Cognitive function in folate-deficient older adults has moderate evidence. Observational studies show associations between low folate status and cognitive decline, and supplementation trials in deficient older adults show some improvements in some cognitive measures. The evidence is substantially limited by small trial sizes, heterogeneous populations and outcome measures, and the frequent co-occurrence of folate and B12 deficiency which makes it difficult to attribute cognitive effects specifically to folate correction. Many trials used combined B-vitamin interventions, further complicating attribution.
Depression symptoms as adjunct treatment shows early-stage and inconsistent evidence. Several small trials have examined methylfolate or folic acid as adjuncts to antidepressant treatment. Effect sizes have been modest and findings inconsistent across trials, many of which have been small, heterogeneous in design, and conducted without adequate characterisation of baseline folate status. Some trials have been industry-linked. The current evidence is more signal-generating than confirmatory and does not support confident claims about efficacy. This remains an active area of research.
Cardiovascular disease prevention is not supported by large controlled trial evidence despite reliable homocysteine reduction. This Insufficient rating is based on two large, well-powered RCTs and multiple meta-analyses with consistent null findings.
What the evidence does not show
Folate supplementation does not prevent cardiovascular disease in the general population. The homocysteine-lowering effect is reliable, but homocysteine appears to be a marker of metabolic dysfunction rather than a causal factor in cardiovascular disease.
Neural tube defect prevention evidence does not extend meaningfully to supplementation initiated after the first six weeks of pregnancy, or to general health outcomes beyond this specific indication.
There is no strong evidence that folate supplementation improves cognitive performance, mood, or energy in individuals with normal folate status.
Form and dose considerations
Folic acid is the form used in all major neural tube defect prevention trials and the form specified in public health guidance. It is stable, inexpensive, and effective for most people. Its higher synthetic bioavailability relative to food folate is an advantage in the periconceptional context where achieving adequate tissue levels is clinically important.
A safety consideration specific to high-dose folic acid: it can correct the haematologic manifestations of B12 deficiency while neurological damage progresses silently. This is particularly relevant in older adults who may be at risk of both low folate and low B12. B12 status should be assessed before initiating high-dose folate supplementation in at-risk populations.
Unmetabolised folic acid circulates in blood following supplementation, particularly at higher doses. The long-term biological significance of this is an area of ongoing research. Current evidence does not establish harm, but it is a reason for not exceeding recommended doses without clinical indication.
Methylfolate (5-MTHF) is the active end form and does not require enzymatic conversion via MTHFR. The mechanistic case for methylfolate over folic acid is most apparent in individuals with the MTHFR C677T homozygous genotype, who have reduced MTHFR enzyme activity and therefore reduced capacity to convert folic acid to 5-MTHF. Methylfolate provides the active form directly and may raise active folate levels more effectively in this population. However, major clinical guidelines including NICE and ACMG do not currently recommend routine MTHFR genotyping to guide supplementation decisions, and direct head-to-head clinical trials comparing methylfolate and folic acid on patient-important outcomes in MTHFR variant populations are limited. The preference for methylfolate in this group is mechanistically plausible but not established by large outcome trials, and should not be presented as a settled clinical recommendation.
For the general population without known MTHFR variants, folic acid remains effective and is the form with the strongest evidence base for neural tube defect prevention specifically.
Folinic acid is occasionally used in clinical settings, including in individuals who do not tolerate folic acid, but it has a smaller evidence base for routine supplementation.
Doses for neural tube defect prevention in standard-risk women are 400 mcg folic acid daily. For women at higher risk, 5 mg daily is recommended. For general deficiency correction, doses in the range of 400 to 1,000 mcg daily are typically used.
Who the evidence applies to
Women planning pregnancy or in the first 12 weeks of pregnancy represent the population with the clearest and most consequential evidence for folate supplementation. This is the indication that has generated the strongest evidence and the broadest public health consensus.
Individuals with the MTHFR C677T homozygous genotype have reduced MTHFR enzyme activity, which impairs the conversion of folic acid to active 5-MTHF. This genetic variant occurs in approximately 10 to 15 per cent of European populations. Methylfolate is mechanistically plausible as a preferred form in this group, though clinical guidelines do not routinely recommend genotyping for supplementation decisions and outcome trial evidence for superiority is limited. This is an area where mechanistic reasoning is ahead of outcomes evidence.
Older adults are at elevated risk of folate deficiency through dietary inadequacy and may have co-occurring B12 deficiency. The interaction between low folate status and cognitive function in older adults makes assessment and correction of deficiency clinically appropriate in this group.
Individuals taking medications that affect folate metabolism include those on methotrexate, which directly inhibits DHFR and depletes folate, anticonvulsants including valproate and phenytoin, and sulfasalazine. These individuals may require folate supplementation under medical supervision.
Generally healthy adults with adequate dietary intake have no established benefit from routine folate supplementation beyond standard dietary amounts, and high-dose supplementation in the absence of deficiency or pregnancy carries the safety considerations noted above.
Testing and status assessment
Serum folate reflects recent dietary intake and can fluctuate with short-term dietary changes. Red cell folate is a more reliable indicator of longer-term tissue folate status and is the preferred marker for assessing deficiency in most clinical contexts. Plasma homocysteine can provide supporting evidence of functional deficiency when folate status is borderline.
MTHFR genotyping is available but is not routinely recommended in most clinical guidelines as a basis for supplementation decisions in the general population. Where it is performed, the C677T polymorphism is the variant with the clearest clinical relevance to folate metabolism.
Safety and contraindications
The most clinically important safety consideration for folate supplementation is its potential to mask B12 deficiency. High-dose folic acid corrects megaloblastic anaemia caused by B12 deficiency, which can delay diagnosis while neurological damage continues. This risk is greatest in older adults, vegans, and others at elevated B12 deficiency risk. B12 status should be evaluated before initiating high-dose folic acid supplementation in these groups.
The upper tolerable intake for folic acid from supplements is 1,000 mcg per day for adults. This limit relates specifically to the risk of masking B12 deficiency rather than to direct toxicity of folate itself.
What can reasonably be concluded
The periconceptional folate evidence is one of the most important and well-established findings in nutritional medicine. Women planning pregnancy should supplement with folic acid before conception and through the first 12 weeks, ideally starting at least one month before conception. This is not a probabilistic recommendation but a well-evidenced clinical standard.
For individuals with the MTHFR C677T homozygous genotype, methylfolate is a mechanistically well-justified alternative to folic acid, though the clinical superiority over folic acid for most outcomes has not been definitively demonstrated in large outcome trials. For most people without known MTHFR variants and not planning pregnancy, the case for routine high-dose folate supplementation is not well-supported.
The homocysteine-lowering effect of folate is reliable but should not be interpreted as evidence of cardiovascular benefit in the absence of direct outcome trial evidence. Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.